The expanding role of immunotherapy in HCC

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Beau Bosko Toskich, M.D., is an interventional radiologist with specialty interest in interventional oncology. His clinical focus includes management of primary and metastatic liver cancer. His research interests include ablative applications of locoregional therapy and immunotherapy. Dr. Toskich has published and presented extensively on liver directed therapy, is the global lead investigator for an international study on combining radioembolizaiton with immunotherapy, has several funded investigator initiated clinical trials, serves on multiple societal and editorial boards, and is regarded as a key opinion leader by the pharmaceutical and medical device industry. He has a joint appointment with both the division of medical oncology and department of radiation oncology.